180 Life Sciences Corp.
ATNF
$0.83
-$0.037-4.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.80M | 4.36M | 4.85M | 6.70M | 8.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.61M | 6.32M | 6.37M | 8.93M | 10.77M |
| Operating Income | -6.61M | -6.32M | -6.37M | -8.93M | -10.77M |
| Income Before Tax | -7.76M | -6.46M | -3.13M | -14.90M | -18.59M |
| Income Tax Expenses | -296.00K | -296.00K | -4.40K | -2.35M | -2.35M |
| Earnings from Continuing Operations | -7.47 | -6.17 | -3.12 | -12.55 | -16.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.47M | -6.17M | -3.12M | -12.55M | -16.24M |
| EBIT | -6.61M | -6.32M | -6.37M | -8.93M | -10.77M |
| EBITDA | -6.54M | -6.25M | -6.29M | -8.83M | -10.66M |
| EPS Basic | -12.46 | -13.47 | -4.49 | -28.16 | -41.54 |
| Normalized Basic EPS | -2.77 | -3.40 | -3.14 | -7.89 | -16.14 |
| EPS Diluted | -12.46 | -13.47 | -4.50 | -28.17 | -41.55 |
| Normalized Diluted EPS | -2.77 | -3.40 | -3.14 | -7.89 | -16.14 |
| Average Basic Shares Outstanding | 6.56M | 3.66M | 3.16M | 2.60M | 1.96M |
| Average Diluted Shares Outstanding | 6.56M | 3.66M | 3.16M | 2.60M | 1.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |